Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.17.21 (
prostate-specific membrane antigen
)
1,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Aspartoacylase
(
ASPA
)-deficient patients [Canavan disease (CD)] reportedly have increased urinary excretion of N-acetylaspartylglutamate (NAAG), a neuropeptide abundant in the brain. Whether elevated excretion of urinary NAAG is due to
ASPA
deficiency, resulting in an abnormal level of brain NAAG, is examined using
ASPA
-deficient mouse brain. The level of NAAG in the knockout mouse brain was similar to that in the wild type. The NAAG hydrolyzing enzyme,
glutamate carboxypeptidase II
(GCP II), activity was normal in the knockout mouse brain. These data suggest that
ASPA
deficiency does not affect the NAAG or GCP II level in the knockout mouse brain, if documented also in patients with CD.
...
PMID:Aspartoacylase deficiency does not affect N-acetylaspartylglutamate level or glutamate carboxypeptidase II activity in the knockout mouse brain. 1524 64
